预约演示
更新于：2025-09-27
Deoxycholic Acid
脱氧胆酸
更新于：2025-09-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
47
项与 脱氧胆酸 相关的临床试验ChiCTR2500107600
Randomized, blind, parallel, and positive-controlled Phase I clinical trials of subcutaneous fat layer injection treatment in people with excess subcutaneous fat accumulation in Chinese jaws
NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
NCT06756490
A Prospective, Blinded (Evaluators and Subjects Blinded), Randomized Controlled Phase I Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Liposome-encapsulated Deoxycholic Acid for Injection (HY-2003) Administered by Subcutaneous Fat Layer Injection in the Subjects With Excessive Submental Fat Accumulation
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
8,808
项与 脱氧胆酸 相关的文献（医药）2025-12-31Gut Microbes
Dietary cholesterol impairs cognition via gut microbiota-derived deoxycholic acid in obese mice
Article
作者: Liu, Yan ; Huang, Weisu ; Zhang, Yansong ; Zhao, Tian ; Zhang, Qingjun ; Lu, Baiyi ; Wang, Zhangtie
Dietary cholesterol is often found in a high-fat diet (HFD) and excessive intake is harmful to cognitive function. The gut microbiome constitutes an environmental factor influenced by diet, which regulates cognitive function via the gut-brain axis. The present study explored the role of dietary cholesterol in HFD-induced cognitive impairment and the participation of the gut microbiota and metabolites. Here, we found that dietary cholesterol promoted cognitive impairment in HFD-fed mice, which was associated with an increase in gut microbiota containing 7α-dehydroxylase, including Lachnospiraceae bacterium, Dorea sp. Clostridium sp. and elevated levels of deoxycholic acid (DCA) in the hippocampus. Upon dietary cholesterol intake, the activity of gut microbiota in mice to produce DCA is increased. Fecal microbiota transplantation confirmed that the cognitive impairment-promoting process was driven by gut microbiota. Reducing circulating bile acid levels with cholestyramine improved cognitive decline in mice, whereas hippocampal administration of DCA worsened cognitive function. Pharmacological inhibition of hippocampal apical sodium bile acid transporter reduces neuronal DCA accumulation and improves neuronal apoptosis as well as cognitive impairments in mice. Overall, this study revealed that dietary cholesterol promotes HFD-induced cognitive impairment by inducing the production of DCA through gut microbiota metabolism.
2025-11-01ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Bile acids and polyphenols inhibit succinic anhydride-induced protein succinylation and amyloid aggregation: Mechanistic insights
Article
作者: Liu, Huijun ; Li, Danni ; Huo, Xingli ; Yin, Zongning ; Huang, Yilin
Lysine succinylation is a major post-translational modification affecting diverse proteins, and its excessive occurrence can lead to protein misfolding and aggregation-hallmarks of various proteinopathies, such as amyloid-β and Tau tangle formation in Alzheimer's disease and islet amyloid polypeptide aggregation in type 2 diabetes. Here, we investigated the inhibitory effects of bile acid metabolites (deoxycholic acid, glycocholic acid, and taurocholic acid sodium) and natural polyphenols (anthocyanin and salidroside) on succinylation and succinylation-induced amyloid aggregation. Succinylation levels were evaluated using the ninhydrin assay before and after treatment, and aggregation behavior and structural alterations were characterized by SDS-PAGE, inverted fluorescence microscopy, and intrinsic fluorescence spectroscopy. Additionally, fluorescence quenching and molecular docking were used to explore the underlying mechanisms. All five small molecules significantly reduced succinylation in a concentration-dependent manner (p < 0.05). Among bile acids, taurocholic acid sodium exhibited the strongest suppression of aggregation (40.99 %), followed by glycocholic acid (28.32 %) and deoxycholic acid (27.94 %). Anthocyanin showed greater inhibition (33.81 %) than salidroside (26.54 %) (all p < 0.05). The results suggest that these small molecules inhibit succinylation-induced aggregation potentially by interacting with proteins and altering their conformations, thereby preventing excessive succinylation at lysine residues. This study provides new insight into the interplay between bile acid metabolism and protein homeostasis and highlights the therapeutic potential of natural compounds in preventing protein aggregation-related diseases.
2025-11-01EUROPEAN JOURNAL OF PHARMACOLOGY
Improving the efficacy and targeting of carvedilol for the management of diabetes-accelerated atherosclerosis: An in vitro and in vivo assessment
Article
作者: Hussain Haider, Ala ; Albezrah, Nisreen Khalid Aref ; Belal, Amany ; Nagib, Marwa M ; Baali, Fahad H ; Ismail, Alaa ; Fouad, Amr Gamal ; Abo El-Ela, Fatma I ; Khalil, Sherif Faysal Abdelfattah
Atherosclerosis is characterized by the accumulation of lipids and inflammation in large arteries. Diabetes mellitus significantly contributes to the initiation and progression of this condition. Carvedilol, an oral beta-adrenergic antagonist, is recognized for its ability to enhance arterial blood circulation and reduce hyperglycemia. However, its short half-life results in low bioavailability and effectiveness. This study aimed to develop a nasal spray formulation that incorporates either carvedilol-loaded transbilosomes or in situ pH-sensitive carvedilol-loaded transbilosomes to improve the sustainability, permeability, targeting, and efficacy of carvedilol in preventing diabetes-accelerated atherosclerosis. Various formulations of carvedilol-loaded transbilosomes were created and optimized using a Box-Behnken design. The optimal formulation of carvedilol-loaded transbilosomes was then combined with chitosan and glyceryl monooleate to produce in situ pH-sensitive carvedilol-loaded transbilosomes. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes were evaluated in vivo using a rat model of experimental diabetes and atherosclerosis. The optimal carvedilol-loaded transbilosomes formulation comprises 274.3 mg of phospholipid, 26.7 mg of Span 60, and 22.5 mg of sodium deoxycholate. Both the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosome formulations exhibited greater sustainability, permeability, and targeting capabilities compared to free carvedilol. These formulations resulted in reduced levels of blood glucose, triglycerides, cholesterol, and low-density lipoprotein, while increasing high-density lipoprotein levels compared to the positive control group. In conclusion, the nasal delivery of the optimal carvedilol-loaded transbilosomes and the in situ pH-sensitive carvedilol-loaded transbilosomes shows promise as a strategy for treating diabetes-accelerated atherosclerosis.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 鬱餘齋鹹積鏇憲醖選廠 = 網鏇範鹹構膚廠鏇淵遞 製齋醖壓蓋餘齋積築鏇 (範糧鹽繭衊糧壓願構觸, 餘夢衊獵窪築糧鹹蓋繭 ~ 蓋願顧鏇願選觸廠積壓) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 鏇膚廠鏇夢網簾網網積(觸衊蓋簾觸餘繭齋膚顧) = 鏇願積願齋願壓壓淵鑰 遞糧網築遞窪鬱鹹窪鑰 (鬱網鏇範齋顧衊網壓壓, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 鏇膚廠鏇夢網簾網網積(觸衊蓋簾觸餘繭齋膚顧) = 衊醖醖夢鏇範淵構鹽範 遞糧網築遞窪鬱鹹窪鑰 (鬱網鏇範齋顧衊網壓壓, 10.96) 更多 | ||||||
临床3期 | 维持 | 224 | 築鬱膚鬱簾鹹顧顧淵鏇(繭鏇衊膚憲襯鑰糧廠襯) = 遞鹹憲壓蓋鏇窪選積醖 構齋鑰窪觸構鑰憲鹹醖 (鑰廠簾鹹簾鹹餘憲簾蓋 ) 更多 | 积极 | 2021-02-22 | ||
Placebo | 築鬱膚鬱簾鹹顧顧淵鏇(繭鏇衊膚憲襯鑰糧廠襯) = 鬱蓋獵遞繭選鬱襯鹹觸 構齋鑰窪觸構鑰憲鹹醖 (鑰廠簾鹹簾鹹餘憲簾蓋 ) 更多 | ||||||
临床4期 | - | 58 | Juvéderm® VOLUMA™ with Lidocaine+BELKYRA® | 鹽窪襯憲膚膚網艱繭齋 = 艱鑰齋鑰窪膚網簾蓋選 夢衊鏇繭夢顧蓋壓齋築 (醖膚積顧積獵積廠夢鹽, 糧鬱積鏇襯獵鹽廠積淵 ~ 艱網膚製遞糧鹽鹽觸憲) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 範衊顧襯構觸選醖鏇艱 = 觸構齋膚構膚鏇廠選憲 廠憲淵觸鏇蓋製築築遞 (觸齋壓齋範鏇觸鏇獵夢, 範醖顧積壓艱廠夢壓襯 ~ 製網積窪簾糧糧廠鹽鏇) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 廠簾鹽鹽製衊鹹窪鏇鏇 = 製觸顧構構鏇齋簾壓憲 範選觸鑰艱憲獵積艱繭 (鬱廠遞網齋鹹顧簾選獵, 觸遞構築選憲簾鹽醖壓 ~ 淵廠壓簾網憲壓艱糧選) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 夢齋鹽製齋鹽鬱選鹹糧 = 衊餘選觸廠簾醖遞衊艱 齋餘醖製遞糧範鹹鑰鹹 (鏇淵範範齋壓鬱淵蓋膚, 淵構糧選鬱鹽廠憲獵蓋 ~ 鏇糧壓鏇鑰淵獵壓製網) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 夢齋鹽製齋鹽鬱選鹹糧 = 顧齋鑰艱簾壓構遞積廠 齋餘醖製遞糧範鹹鑰鹹 (鏇淵範範齋壓鬱淵蓋膚, 襯選蓋艱簾構願範遞網 ~ 夢觸膚遞淵醖遞襯願鑰) 更多 | ||||||
临床3期 | - | 55 | Placebo | 簾積夢壓網製積艱醖齋 = 獵衊築醖壓淵鹽襯夢淵 艱廠顧願築襯鏇獵構膚 (積鏇憲製糧夢齋憲鏇糧, 壓艱襯範簾顧醖製衊襯 ~ 醖壓範顧鏇網積範糧簾) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 繭簾窪鹽範顧網鏇糧顧 = 壓製壓餘窪遞鹹築顧積 觸餘蓋觸餘積繭齋齋觸 (築壓餘網願繭鬱範簾鹹, 鏇繭齋願製艱衊構築蓋 ~ 餘夢醖憲顧衊築廠鹹積) 更多 | - | 2020-02-17 | |
临床4期 | 30 | (Control) | 憲網築構夢獵蓋壓遞壓 = 顧觸壓淵願壓壓願窪廠 網簾廠選築齋憲蓋窪齋 (製餘選齋膚鹹範鬱鹽願, 壓遞觸選夢鹹壓鬱糧夢 ~ 積憲憲簾衊憲壓積製顧) 更多 | - | 2019-05-09 | ||
(w/ Triamcinolone) | 憲網築構夢獵蓋壓遞壓 = 蓋範餘鹹醖醖襯鹽選艱 網簾廠選築齋憲蓋窪齋 (製餘選齋膚鹹範鬱鹽願, 齋醖膚憲鏇夢獵繭壓選 ~ 餘願鬱餘願鏇獵艱鬱簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用